Skip to main content

Cepheid Shares Jump 8.9 Percent After Investment Bank Upgrades Stock

NEW YORK, Jan. 5 (GenomeWeb News) - UBS today upgraded Cepheid's stock to 'Buy' from 'Neutral' claiming changes in the company's valuation make the stock more attractive.

 

Shares in Cepheid were up 8.9 percent, or $.79, to $9.75 in mid-afternoon trading.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.